{"id":"tamoxifen-alone","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Hot flashes"},{"rate":"20-30","effect":"Vaginal discharge"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Vaginal bleeding"},{"rate":"1-3","effect":"Endometrial cancer"},{"rate":"1-3","effect":"Thromboembolic events"},{"rate":"10-20","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL83","moleculeType":"Small molecule","molecularWeight":"371.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamoxifen competitively binds to estrogen receptors (ER) on hormone-responsive breast cancer cells, preventing endogenous estrogen from activating these receptors and promoting cell proliferation. By blocking ER signaling, it induces cell cycle arrest and apoptosis in ER-positive breast cancer cells. It has mixed agonist/antagonist activity depending on tissue type, acting as an antagonist in breast tissue but with some agonist effects in other tissues.","oneSentence":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:20.572Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (adjuvant and metastatic)"},{"name":"Breast cancer prevention in high-risk women"}]},"trialDetails":[{"nctId":"NCT06184750","phase":"PHASE2","title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma","enrollment":200},{"nctId":"NCT06944145","phase":"PHASE2","title":"New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2025-12-03","conditions":"BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms","enrollment":242},{"nctId":"NCT01788839","phase":"","title":"Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-02","conditions":"Breast Cancer, Lymphoma, Hodgkin's Lymphoma","enrollment":475},{"nctId":"NCT07447024","phase":"NA","title":"Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-02","conditions":"Mastectomy","enrollment":60},{"nctId":"NCT04852887","phase":"PHASE3","title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-07","conditions":"Stage I Breast Cancer","enrollment":1670},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT02747004","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-09-14","conditions":"Metastatic Breast Cancer","enrollment":234},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT02668666","phase":"PHASE2","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Oana Danciu, MD","startDate":"2017-02-01","conditions":"Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer","enrollment":49},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05501704","phase":"PHASE2","title":"ETHAN - ET for Male BC","status":"RECRUITING","sponsor":"Jose Pablo Leone","startDate":"2023-10-11","conditions":"Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT05035836","phase":"PHASE2","title":"A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-11-16","conditions":"Breast Cancer, HER2-positive","enrollment":20},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT05607004","phase":"PHASE2","title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Atossa Therapeutics, Inc.","startDate":"2023-02-14","conditions":"Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer","enrollment":87},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT00601900","phase":"PHASE3","title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-09-24","conditions":"Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6","enrollment":394},{"nctId":"NCT02764541","phase":"PHASE2","title":"Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-05-24","conditions":"Breast Cancer","enrollment":195},{"nctId":"NCT03820830","phase":"PHASE3","title":"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-08-27","conditions":"Breast Cancer Recurrent","enrollment":405},{"nctId":"NCT01745965","phase":"PHASE2","title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-11","conditions":"Breast Cancer","enrollment":380},{"nctId":"NCT04312399","phase":"NA","title":"Hormone Replacement Trial Against ALzheimers' Disease","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-04-17","conditions":"Postmenopausal Symptoms, Alzheimer Disease","enrollment":600},{"nctId":"NCT04915846","phase":"PHASE1, PHASE2","title":"Tamoxifen Therapy for Myotubular Myopathy","status":"TERMINATED","sponsor":"James Dowling","startDate":"2020-12-18","conditions":"X Linked Myotubular Myopathy","enrollment":6},{"nctId":"NCT02188745","phase":"PHASE2","title":"ER Reactivation Therapy for Breast Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03-11","conditions":"Metastatic Breast Cancer","enrollment":19},{"nctId":"NCT03382834","phase":"PHASE2","title":"Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-26","conditions":"HIV Infections","enrollment":31},{"nctId":"NCT01573637","phase":"PHASE3","title":"Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2011-07","conditions":"Schizophrenia in Post Menopausal Women","enrollment":78},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT05386784","phase":"PHASE4","title":"Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-12-16","conditions":"Postemenopusal Women With Osteopenia","enrollment":112},{"nctId":"NCT06355401","phase":"PHASE2, PHASE3","title":"Maintenance Hormonal Therapy and DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2024-04","conditions":"Diffuse Large B Cell Lymphoma","enrollment":100},{"nctId":"NCT03423199","phase":"PHASE3","title":"PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2018-02-09","conditions":"Breast Neoplasms","enrollment":180},{"nctId":"NCT00295646","phase":"PHASE3","title":"Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1999-06","conditions":"Breast Cancer","enrollment":1803},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT00424164","phase":"PHASE1","title":"Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-11","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT04961632","phase":"PHASE1","title":"Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2020-12-23","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT05172050","phase":"PHASE2, PHASE3","title":"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2021-01-22","conditions":"SARS CoV 2 Infection","enrollment":61},{"nctId":"NCT05525481","phase":"PHASE4","title":"Tamoxifen Prediction Study in Patients With ER+ Breast Cancer","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2022-11-01","conditions":"ER+ Breast Cancer","enrollment":100},{"nctId":"NCT01298713","phase":"PHASE2","title":"Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2008-03","conditions":"Breast Neoplasms, mTor Protein","enrollment":111},{"nctId":"NCT05983107","phase":"PHASE2","title":"Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-07-20","conditions":"HR+/HER2- Advanced Breast Cancer, Targeted Therapy","enrollment":102},{"nctId":"NCT01124695","phase":"PHASE2","title":"Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-01-07","conditions":"Breast Cancer, Stage IV Breast Cancer","enrollment":124},{"nctId":"NCT05890287","phase":"NA","title":"A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-16","conditions":"HR Positive HER2 Negative Advanced Breast Cancer","enrollment":60},{"nctId":"NCT02285179","phase":"PHASE1, PHASE2","title":"Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2014-11","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT02734615","phase":"PHASE1","title":"Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-14","conditions":"Advanced or Metastatic ER+ Breast Cancer","enrollment":199},{"nctId":"NCT00003857","phase":"PHASE3","title":"Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1999-12","conditions":"Breast Cancer","enrollment":636},{"nctId":"NCT04666961","phase":"PHASE2","title":"Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ","status":"RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2021-02-03","conditions":"Ductal Carcinoma in Situ, Extensive Disease, Mastectomy","enrollment":262},{"nctId":"NCT00710970","phase":"PHASE2","title":"Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment","status":"COMPLETED","sponsor":"Seth Lerner","startDate":"2007-01","conditions":"Urinary Bladder Neoplasms","enrollment":28},{"nctId":"NCT02366130","phase":"PHASE2","title":"Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-02-11","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT02603679","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-02","conditions":"Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor","enrollment":181},{"nctId":"NCT02936206","phase":"PHASE1","title":"Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-10","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT02197897","phase":"PHASE2","title":"Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2015-04-01","conditions":"Bladder Cancer","enrollment":15},{"nctId":"NCT02517593","phase":"PHASE1, PHASE2","title":"Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-03","conditions":"Breast Cancer","enrollment":151},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00309491","phase":"PHASE3","title":"Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1990-12","conditions":"Early-stage Breast Cancer","enrollment":2021},{"nctId":"NCT04488107","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c","status":"UNKNOWN","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2019-02-14","conditions":"Breast Neoplasms","enrollment":78},{"nctId":"NCT02592083","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-10","conditions":"Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor","enrollment":10},{"nctId":"NCT02058381","phase":"PHASE1","title":"A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-06","conditions":"Pre-menopausal Breast Cancer, PI3K Pathway Inhibition","enrollment":40},{"nctId":"NCT02093351","phase":"PHASE1","title":"To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-01","conditions":"Solid Tumours","enrollment":79},{"nctId":"NCT03764462","phase":"PHASE1","title":"Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2018-12-14","conditions":"Osteoporosis","enrollment":52},{"nctId":"NCT03824171","phase":"PHASE1","title":"Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2019-02-28","conditions":"Osteoporosis","enrollment":52},{"nctId":"NCT00041080","phase":"PHASE3","title":"Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-02","conditions":"Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer","enrollment":139},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT03058939","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2018-11","conditions":"Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":""},{"nctId":"NCT01685255","phase":"PHASE2","title":"A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2012-08","conditions":"Ovarian Cancer, Genitourinary (GU) Tumors","enrollment":83},{"nctId":"NCT03750396","phase":"PHASE2","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2018-08-01","conditions":"Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy","enrollment":110},{"nctId":"NCT01973660","phase":"PHASE2","title":"PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2013-10","conditions":"Breast Cancer","enrollment":151},{"nctId":"NCT01638247","phase":"PHASE3","title":"Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-08","conditions":"Male Breast Cancer","enrollment":56},{"nctId":"NCT00728949","phase":"PHASE2","title":"A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Metastatic Breast Cancer","enrollment":93},{"nctId":"NCT02404844","phase":"PHASE2","title":"Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2014-12","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT00118157","phase":"PHASE2","title":"Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-05","conditions":"Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive","enrollment":19},{"nctId":"NCT01712893","phase":"PHASE3","title":"Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-06","conditions":"Breast Cancer","enrollment":216},{"nctId":"NCT01266213","phase":"PHASE2","title":"Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2010-12","conditions":"Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal","enrollment":147},{"nctId":"NCT01419197","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":602},{"nctId":"NCT02271282","phase":"PHASE1","title":"Estradiol-Receptor Blockade in Older Men and Women","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-12","conditions":"Normal Healthy Volunteers","enrollment":40},{"nctId":"NCT02479256","phase":"PHASE4","title":"Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2015-06","conditions":"PCOS","enrollment":600},{"nctId":"NCT02654093","phase":"PHASE1","title":"A Drug-drug Interaction Study of DP-R213","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2016-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01821066","phase":"PHASE1","title":"A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Healthy","enrollment":25},{"nctId":"NCT00214110","phase":"PHASE2","title":"Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2001-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":100},{"nctId":"NCT00999921","phase":"PHASE4","title":"Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer","status":"COMPLETED","sponsor":"Medical College and Hospital Kolkata","startDate":"2008-01","conditions":"Benign Breast Disease, Fibrocystic Disease of Breast, Fibroadenoma","enrollment":256},{"nctId":"NCT02313051","phase":"PHASE2","title":"Everolimus trIal for Advanced prememopausaL Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-12","conditions":"Metastatic Breast Cancer","enrollment":200},{"nctId":"NCT00165308","phase":"NA","title":"Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-04","conditions":"Hodgkin's Disease, Breast Cancer","enrollment":29},{"nctId":"NCT00002720","phase":"PHASE3","title":"Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer","status":"COMPLETED","sponsor":"European Institute of Oncology","startDate":"1995-12","conditions":"Breast Cancer","enrollment":642},{"nctId":"NCT00002967","phase":"PHASE3","title":"Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"1997-05","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00897091","phase":"","title":"S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2006-07","conditions":"Breast Cancer","enrollment":750},{"nctId":"NCT00002529","phase":"PHASE3","title":"Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"1993-05","conditions":"Breast Cancer","enrollment":452},{"nctId":"NCT00002528","phase":"PHASE3","title":"Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"1993-05","conditions":"Breast Cancer","enrollment":473},{"nctId":"NCT00929591","phase":"PHASE3","title":"SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1989-05","conditions":"Breast Cancer","enrollment":1558},{"nctId":"NCT00016276","phase":"PHASE3","title":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-05","conditions":"Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer","enrollment":396},{"nctId":"NCT00002920","phase":"PHASE3","title":"S9630, Medroxyprogesterone in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1997-03","conditions":"Breast Cancer, Endometrial Cancer","enrollment":313},{"nctId":"NCT00849030","phase":"PHASE3","title":"ATAC - Arimidex, Tamoxifen Alone or in Combination","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1996-07","conditions":"Breast Cancer","enrollment":9358},{"nctId":"NCT00031811","phase":"NA","title":"Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2001-03","conditions":"Breast Cancer, Menopausal Symptoms, Osteoporosis","enrollment":80},{"nctId":"NCT00431444","phase":"PHASE4","title":"Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Osteoporosis","enrollment":110},{"nctId":"NCT01169792","phase":"","title":"Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"","conditions":"Breast Neoplasms, Survival Analysis, Antineoplastic Agents","enrollment":""},{"nctId":"NCT00912548","phase":"PHASE3","title":"Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women","status":"UNKNOWN","sponsor":"Korean Breast Cancer Study Group","startDate":"2009-05","conditions":"Breast Cancer","enrollment":1234},{"nctId":"NCT00784862","phase":"PHASE3","title":"ATAC - Pharmacokinetics (PK) Sub-Protocol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1998-06","conditions":"Breast Cancer","enrollment":9358},{"nctId":"NCT00784680","phase":"PHASE3","title":"ATAC - Quality of Life Sub-Protocol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1998-04","conditions":"Quality of Life","enrollment":308},{"nctId":"NCT00814125","phase":"PHASE3","title":"ATAC - Endometrial Sub-Protocol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1997-06","conditions":"Breast Cancer","enrollment":285},{"nctId":"NCT00784940","phase":"PHASE3","title":"ATAC - Bone Density Sub-Protocol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"1998-06","conditions":"Bone Density","enrollment":308}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":624,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nolvadex"],"phase":"phase_3","status":"active","brandName":"Tamoxifen alone","genericName":"Tamoxifen alone","companyName":"Austrian Breast & Colorectal Cancer Study Group","companyId":"austrian-breast-colorectal-cancer-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth. Used for Hormone receptor-positive breast cancer (adjuvant and metastatic), Breast cancer prevention in high-risk women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}